---
title: "Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic impact on families"
description: "Formulary evidence on Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic impact on families. Topics: Caregiver time, finances, and employment; Prevalence of high financial toxicity and coping behaviors; Indirect costs and the role of informal caregivers; Out-of-pocket payments for oral androgen receptor pathway inhibitors under Medicare Part D; 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-15T21:45:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide on Families

<a id="topic-2.2.1.8.3-1"></a>

### Caregiver time, finances, and employment

> “Caregivers often spouses or partners, provide practical, financial, and emotional support, averaging 11 hours/week of providing care.”
> “For the majority of caregivers (58% to 60%), providing care affects their finances (60%), sleep (60%), energy level (59%), mood/mental health (58%), and overall day-to-day life (58%). More than half of caregivers (53%) report an impact on their ability to work.”
> “Among the 79% of caregivers who worked outside the home before their patient’s mCRPC diagnosis, 40% reduced their working hours, 13% stopped working completely, 3% retired as planned, and 43% made other changes; only 15% continued working normally post-diagnosis (Supplementary Table S1). Among those who reduced work hours, 64% reduced their hours by half or more.”

Source: [Jain et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12218467/)

<a id="topic-2.2.1.8.3-2"></a>

### Prevalence of high financial toxicity and coping behaviors

> “Overall, 281 patients met inclusion criteria of which 79 reported high financial toxicity.”
> “Patients with high financial toxicity were more likely to decrease spending on basic goods (35% vs 2.5%, P < .001) and leisure activities (59% vs 15%, P > .001), as well as use savings (62% vs 17%, P < .001) to pay for their treatment.”

Source: [Joyce et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37416955/)

<a id="topic-2.2.1.8.3-3"></a>

### Indirect costs and the role of informal caregivers

> “Qualitative descriptions were congruent with quantitative items assessing indirect costs of treatment, with many patients describing alterations to work, early retirement, and caregiver lifestyle changes (Quotes 1.2.2, 1.2.3, 1.2.5). Additional indirect costs not evaluated by the quantitative assessment included the opportunity cost of time spent navigating insurance coverage, as well as costs of travel to treatment sites, including gas, commute time, hotel expenses, and even relocating to be closer to care (Quotes 1.2.2, 1.2.4, 1.2.7).”
> “In addition, how treatment costs impacted the lives of patients’ loved ones was a strong contributor to the degree of financial stress that they experienced (Quotes 3.3.3, 3.3.4).”

Source: [Joyce et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11192241/)

<a id="topic-2.2.1.8.3-4"></a>

### Out-of-pocket payments for oral androgen receptor pathway inhibitors under Medicare Part D

> “There were 4,153 patients who filled abiraterone or enzalutamide through Medicare Part D in 228 hospital-referral regions. Mean adherence was 75%. Median monthly out-of-pocket payment for abiraterone and enzalutamide was $706 (range $0 to $3,505).”

Source: [Caram et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7959094/)

<a id="topic-2.2.1.8.3-5"></a>

### Out-of-pocket payments by first-line agent: employer-sponsored insurance

> “OOP payments were lower than gross drug payments; mean 6-month OOP payments were highest for cabazitaxel ($1,044 USD) and lowest for docetaxel ($296 USD). There was a wide distribution of OOP payments within drug types.”

Source: [Kaye et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10113111/)

## Related pages
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Terms and abbreviations](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/terms-and-abbreviations.md)
- [Rinzimetostat (ORIC-944): Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/executive-summary.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Product information and disease description](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/product-information-and-disease-description.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Clinical evidence](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/clinical-evidence.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: Economic information and modeling report](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/economics.md)
- [Rinzimetostat (ORIC-944) in Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide: References](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references) · [Markdown](https://www.evicenter.com/drugs/rinzimetostat--metastatic-castration-resistant-prostate-cancer-previously-treated-with-abiraterone-in-combination-with-darolutamide/references.md)
